Dutch drug developer AM-Pharma has raised 7.0 million euros ($11.0 million) as part of the first close of a series C financing round. The biopharmaceutical company, which is developing improved endogenous proteins and peptides to combat disease, signed the agreement with Forbion Capital Partners and Inventages Venture Capital.
The investment is part of a round of 20.0 million euros. The firm says it is in active discussion with several potential investors from both Europe and the USA on another 13.0 million euros in a second close of the series C financing. Investors in the second close will be allowed to the same terms and conditions that apply to the first round.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze